Dyne Therapeutics Inc (DYN) Quarterly Institutional 13F Update (Q2 2026)

DYN ranks #2505 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

DYN is a top-conviction position for Atlas Venture Life Science Advisors, LLC — at 17.1% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in DYN belongs to T. Rowe Price Investment Management, Inc., but the position matters far more to Atlas Venture Life Science Advisors, LLC, who has 17.1% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

IFP Advisors, Inc has added to its DYN position for two straight quarters, increasing it by $26.4K to reach $94.7K today.

Essential Partners LLC has trimmed its DYN position for two straight quarters, cutting it by $7.2K while still holding $886.0.

DYN is down 6.8% today, but institutions show net buying of $224.4M this quarter — a divergence between today's price move and the underlying institutional flow.

DYN reported a net loss of $446.2M in its latest fiscal year.

• Not yet profitable — net loss of $446.2M in the latest fiscal year
• Net income declined year over year, from -$317.4M to -$446.2M
• Operating cash flow was negative, using $403.2M in cash
• Current ratio of 22.25x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.22x equity — within a conventional range